CCM
LEGN icon

Consonance Capital Management’s Legend Biotech LEGN Stock Holding History

Consonance Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,647,497
Closed -$67.6M – 22
2021
Q2 		$67.6M Buy
1,647,497
+750,889
+84% +$25.5M 8.14% 5
2021
Q1 		$26M Buy
+896,608
New +$24.5M 2.77% 14

Other funds holding LEGN

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Consonance Capital Management's LEGN Position: Q3 2021 in Review

Consonance Capital Management sold out of Legend Biotech (LEGN) in Q3 2021, closing a stake of 1,647,497 shares — an estimated $67.6M sold.

Consonance Capital Management first reported a position in LEGN in Q1 2021 and held it in 2 quarters. The position peaked at $67.6M in Q2 2021. 88 funds tracked by Wall St. Rank hold LEGN as of Q3 2021.

  • Consonance Capital Management reported no remaining Legend Biotech position as of Q3 2021 after selling out during the quarter.
  • Consonance Capital Management sold 1,647,497 Legend Biotech shares in Q3 2021, an estimated $67.6M.
  • Consonance Capital Management first reported a position in Legend Biotech in Q1 2021 and held it in 2 quarters.
  • Consonance Capital Management's Legend Biotech position peaked at $67.6M in Q2 2021.
  • 88 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2021.

Based on Consonance Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.